The Trump administration’s flagship budget package, dubbed the One Big Beautiful Bill Act, is advancing through Congress and is currently awaiting a vote in the Senate. The bill includes the biggest ...

This week, Congress reached a bipartisan healthcare deal as part of a larger $1.2 trillion spending bill, combining funding ...

Cancer drugs are always popular biotech investments, but autoimmune disease also figures prominently in the startup ...

President Donald Trump unveiled the Great Healthcare Plan to lower drug costs and insurance premiums, but healthcare ...

BioNTech’s oncology strategy centers on a bispecific antibody that the company envisions as the backbone of many potential drug combinations for many types of cancer. Bristol Myer Squibb is buying ...

Epic Systems and several healthcare providers have sued Health Gorilla and other companies, alleging they exploited ...

The prosthetics field’s main problem isn’t just designing better devices — it’s the lack of data to guide which device is best for each patient, according to one executive in the space. Josh Caputo, ...

Bristol Myers Squibb hasn’t had much luck with its efforts to develop cancer treatments called T cell engagers. But the pharmaceutical company isn’t done pursuing this type of targeted cancer therapy, ...

An Astellas Pharma drug designed to address a novel target has landed a highly anticipated FDA approval for a rare type of gastrointestinal cancer, making it the first therapy in a new class of ...

AI rivals Anthropic and OpenAI are both expanding their large language models into healthcare. Anthropic is blending its enterprise and consumer tools in a single platform, while OpenAI is separating ...

A Roche drug that is one of the company’s top cancer products is expanding to autoimmune disease with a new FDA approval in lupus nephritis. The intravenously infused drug, Gazyva, may now be used to ...